IL105472A - Medicament composition for suppression of t-cell proliferation and immune response against introduction of non-self tissue containing major histocompatibility complex class ii antigens or synthetic peptides corresponding to class ii antigens - Google Patents

Medicament composition for suppression of t-cell proliferation and immune response against introduction of non-self tissue containing major histocompatibility complex class ii antigens or synthetic peptides corresponding to class ii antigens

Info

Publication number: IL105472A
Authority: IL; Israel
Prior art keywords: mammal; class; peptide; antigen; histocompatibility complex
Prior art date: 1992-04-20

Application number

IL10547293A

Other languages

English (en)

Other versions

IL105472A0 (en

Original Assignee

Autoimmune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-20

Filing date

1993-04-20

Publication date

1999-06-20

1993-04-20 Application filed by Autoimmune Inc filed Critical Autoimmune Inc

1993-08-18 Publication of IL105472A0 publication Critical patent/IL105472A0/xx

1999-06-20 Publication of IL105472A publication Critical patent/IL105472A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 64
239000000427 antigen Substances 0.000 title claims abstract description 21
108091007433 antigens Proteins 0.000 title claims abstract description 20
102000036639 antigens Human genes 0.000 title claims abstract description 20
230000028993 immune response Effects 0.000 title claims abstract description 10
102000018713 Histocompatibility Antigens Class II Human genes 0.000 title claims abstract 5
108010027412 Histocompatibility Antigens Class II Proteins 0.000 title claims abstract 5
102000043131 MHC class II family Human genes 0.000 title claims abstract 4
108091054438 MHC class II family Proteins 0.000 title claims abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title claims description 39
239000003814 drug Substances 0.000 title claims description 10
239000000203 mixture Substances 0.000 title abstract description 43
230000006052 T cell proliferation Effects 0.000 title description 2
230000001629 suppression Effects 0.000 title description 2
230000004044 response Effects 0.000 claims abstract description 34
241000124008 Mammalia Species 0.000 claims abstract description 30
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 14
230000035755 proliferation Effects 0.000 claims abstract description 14
239000012634 fragment Substances 0.000 claims abstract description 13
230000000638 stimulation Effects 0.000 claims abstract 3
108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 50
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 49
230000000735 allogeneic effect Effects 0.000 claims description 21
241000700159 Rattus Species 0.000 claims description 16
125000003275 alpha amino acid group Chemical group 0.000 claims description 6
150000001413 amino acids Chemical class 0.000 claims description 6
238000000034 method Methods 0.000 abstract description 3
241001465754 Metazoa Species 0.000 description 47
210000004027 cell Anatomy 0.000 description 30
208000027930 type IV hypersensitivity disease Diseases 0.000 description 26
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 25
230000005951 type IV hypersensitivity Effects 0.000 description 25
210000004988 splenocyte Anatomy 0.000 description 22
230000009467 reduction Effects 0.000 description 21
238000002474 experimental method Methods 0.000 description 18
210000004698 lymphocyte Anatomy 0.000 description 16
238000000338 in vitro Methods 0.000 description 12
238000001727 in vivo Methods 0.000 description 12
230000002163 immunogen Effects 0.000 description 9
230000005847 immunogenicity Effects 0.000 description 9
238000001990 intravenous administration Methods 0.000 description 8
MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 8
230000003053 immunization Effects 0.000 description 7
238000002649 immunization Methods 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
230000000747 cardiac effect Effects 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000187479 Mycobacterium tuberculosis Species 0.000 description 5
239000004677 Nylon Substances 0.000 description 5
230000000961 alloantigen Effects 0.000 description 5
201000002491 encephalomyelitis Diseases 0.000 description 5
230000006698 induction Effects 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
229920001778 nylon Polymers 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
239000005844 Thymol Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
210000000612 antigen-presenting cell Anatomy 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000013642 negative control Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
229960000790 thymol Drugs 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
102100037850 Interferon gamma Human genes 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
108090000978 Interleukin-4 Proteins 0.000 description 3
206010070834 Sensitisation Diseases 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
230000004046 hyporesponsiveness Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
230000021633 leukocyte mediated immunity Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
230000008313 sensitization Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000012360 testing method Methods 0.000 description 3
208000009386 Experimental Arthritis Diseases 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
230000017274 T cell anergy Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000002992 thymic effect Effects 0.000 description 2
230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
230000003614 tolerogenic effect Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
101100460844 Mus musculus Nr2f6 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007659 Protein Deglycase DJ-1 Human genes 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102000009661 Repressor Proteins Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000781 anti-lymphocytic effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
108010083127 phage repressor proteins Proteins 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000008884 pinocytosis Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000003375 selectivity assay Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Developmental Biology & Embryology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Transplantation (AREA)
Mycology (AREA)
Virology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Plant Substances (AREA)

IL10547293A 1992-04-20 1993-04-20 Medicament composition for suppression of t-cell proliferation and immune response against introduction of non-self tissue containing major histocompatibility complex class ii antigens or synthetic peptides corresponding to class ii antigens IL105472A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US87128992A	1992-04-20	1992-04-20
US96177992A	1992-10-15	1992-10-15
US97773792A	1992-11-13	1992-11-13
US08/027,127 US5593698A (en)	1990-10-31	1993-03-05	Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides

Publications (2)

Publication Number	Publication Date
IL105472A0 IL105472A0 (en)	1993-08-18
IL105472A true IL105472A (en)	1999-06-20

Family

ID=27487557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10547293A IL105472A (en)	1992-04-20	1993-04-20	Medicament composition for suppression of t-cell proliferation and immune response against introduction of non-self tissue containing major histocompatibility complex class ii antigens or synthetic peptides corresponding to class ii antigens

Country Status (13)

Country	Link
US (1)	US5593698A (pt)
EP (1)	EP0637249B1 (pt)
JP (1)	JPH07505892A (pt)
KR (1)	KR100275656B1 (pt)
AT (1)	ATE205400T1 (pt)
AU (1)	AU686101B2 (pt)
BR (1)	BR9306345A (pt)
CA (1)	CA2118502A1 (pt)
DE (1)	DE69330752D1 (pt)
HU (1)	HUT71310A (pt)
IL (1)	IL105472A (pt)
NO (1)	NO943967L (pt)
WO (1)	WO1993020842A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6156306A (en) *	1994-08-17	2000-12-05	Albert Einstein College Of Medicine Of Yeshiva University	Pancreatic β-cells for allogeneic transplantation without immunosuppression
GB9505784D0 (en) *	1995-03-22	1995-05-10	Lynxvale Ltd	Anti-tumour treatment
US7361331B2 (en) *	1996-10-18	2008-04-22	Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food	Plant bioreactors
US6617171B2 (en) *	1998-02-27	2003-09-09	The General Hospital Corporation	Methods for diagnosing and treating autoimmune disease
US6599710B1 (en)	1999-03-10	2003-07-29	The General Hospital Corporation	Treatment of autoimmune disease
AU2001245848A1 (en) *	2000-03-15	2001-10-23	Advanced Research And Technology Institute	Oral tolerance induction by collagen to prevent allograft rejection
US7348005B2 (en) *	2000-03-15	2008-03-25	Advanced Research And Technology Institute	Oral tolerance induction by collagen to prevent allograft rejection
US7261896B2 (en)	2000-05-24	2007-08-28	United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health	Methods for preventing strokes by inducing tolerance to e-selectin
CN102764425B (zh) *	2000-08-21	2015-11-25	阿皮托普技术(布里斯托尔)有限公司	肽选择方法
US7628988B2 (en)	2002-06-27	2009-12-08	The General Hospital Corporation	Methods and compositions for treating type 1 diabetes
US7582313B2 (en)	2002-06-27	2009-09-01	The General Hospital Corporation	Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004045376A2 (en) *	2002-11-15	2004-06-03	The General Hospital Corporation	Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) *	2005-01-18	2008-05-01	Faustman Denise L	Compositions Containing Agm Cells And Methods Of Use Thereof
GB0710529D0 (en)	2007-06-01	2007-07-11	Circassia Ltd	Vaccine
NZ583362A (en)	2007-08-15	2012-06-29	Circassia Ltd	Peptide with reduced dimer formation
EP3936137A1 (en)	2013-02-07	2022-01-12	The General Hospital Corporation	Methods for expansion or depletion of t-regulatory cells
CN111879948A (zh)	2013-10-17	2020-11-03	综合医院公司	鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
ES2702676T3 (es) *	2014-04-01	2019-03-04	Inst Nat Sante Rech Med	Péptido de donante aislado derivado de MHC y usos del mismo
CN115043943A (zh)	2015-05-15	2022-09-13	综合医院公司	拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en)	2015-08-28	2019-05-09	The General Hospital Corporation	Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (en)	2015-09-29	2024-03-06	The General Hospital Corporation	A composition comprising bcg for reducing cholesterol.
US11859002B2 (en)	2016-05-13	2024-01-02	The General Hospital Corporation	Antagonistic anti-tumor necrosis factor receptor 2 antibodies
CN113302205B (zh)	2018-11-15	2024-12-06	综合医院公司	激动性肿瘤坏死因子受体超家族多肽

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5364762A (en) *	1990-03-21	1994-11-15	Board Of Trustees Of The Leland Stanford Junior University	Major histocompatibility complex (MHC) molecules

1993
- 1993-03-05 US US08/027,127 patent/US5593698A/en not_active Expired - Fee Related
- 1993-04-20 HU HU9403006A patent/HUT71310A/hu unknown
- 1993-04-20 DE DE69330752T patent/DE69330752D1/de not_active Expired - Lifetime
- 1993-04-20 IL IL10547293A patent/IL105472A/en not_active IP Right Cessation
- 1993-04-20 WO PCT/US1993/003708 patent/WO1993020842A1/en not_active Ceased
- 1993-04-20 EP EP93910671A patent/EP0637249B1/en not_active Expired - Lifetime
- 1993-04-20 BR BR9306345A patent/BR9306345A/pt not_active Application Discontinuation
- 1993-04-20 KR KR1019940703715A patent/KR100275656B1/ko not_active Expired - Fee Related
- 1993-04-20 AT AT93910671T patent/ATE205400T1/de not_active IP Right Cessation
- 1993-04-20 CA CA002118502A patent/CA2118502A1/en not_active Abandoned
- 1993-04-20 JP JP5518673A patent/JPH07505892A/ja not_active Ceased
- 1993-04-20 AU AU41083/93A patent/AU686101B2/en not_active Ceased
1994
- 1994-10-19 NO NO943967A patent/NO943967L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL105472A0 (en)	1993-08-18
DE69330752D1 (de)	2001-10-18
EP0637249A1 (en)	1995-02-08
JPH07505892A (ja)	1995-06-29
EP0637249A4 (en)	1997-01-08
HUT71310A (en)	1995-11-28
WO1993020842A1 (en)	1993-10-28
AU686101B2 (en)	1998-02-05
HU9403006D0 (en)	1994-12-28
ATE205400T1 (de)	2001-09-15
US5593698A (en)	1997-01-14
NO943967D0 (no)	1994-10-19
CA2118502A1 (en)	1993-10-28
BR9306345A (pt)	1998-06-30
AU4108393A (en)	1993-11-18
EP0637249B1 (en)	2001-09-12
KR950701228A (ko)	1995-03-23
KR100275656B1 (ko)	2000-12-15
NO943967L (no)	1994-10-19

Legal Events

Date	Code	Title
1999-10-28	FF	Patent granted
2000-06-29	KB	Patent renewed
2003-07-06	KB	Patent renewed
2008-01-06	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5593698A (en)	1997-01-14	Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
Sayegh et al.	1996	Role of indirect allorecognition in allograft rejection
Afzali et al.	2008	Pathways of major histocompatibility complex allorecognition
Allez et al.	2004	Regulatory T cells: peace keepers in the gut
EP1301202B1 (en)	2011-01-05	Genetically-engineered mhc molecules
US5681556A (en)	1997-10-28	Method and compositions for suppressing allograft rejection in mammals
Dong et al.	1999	Transplantation tolerance: the concept and its applicability
Bharat et al.	2007	Allopeptides and the alloimmune response
CA2110055C (en)	2002-08-20	T cell receptor peptides as therapeutics for immune-related disease
Miller et al.	1993	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization
Miller et al.	1991	Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases
US5961977A (en)	1999-10-05	Method of treating or preventing autoimmune uveoretinitis in mammals
Zavazava et al.	2000	Oral feeding of an immunodominant MHC donor-derived synthetic class I peptide prolongs graft survival of heterotopic cardiac allografts in a high-responder rat strain combination
Ohm et al.	2025	Chimerism and immunological tolerance in solid organ transplantation
Murphy et al.	1996	T CELL RECOGNITION OF XENO-MHC PEPTIDES DURING CONCORDANT XENOGRAFT REJECTION1
Benichou et al.	1998	The presentation of self and allogeneic MHC peptides to T lymphocytes
Oluwole et al.	2003	CD4+ CD25+ regulatory T cells mediate acquired transplant tolerance
Saborio et al.	1999	Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides
EP0883406A1 (fr)	1998-12-16	Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
Ten Berge et al.	1982	A longitudinal study on the effects of azathioprine and high doses of prednisone on the immune system of kidney-transplant recipients
Murphy et al.	1996	Immunomodulatory function of major histocompatibility complexderived peptides
Kozovska et al.	1996	TT cellular interaction between CD4-CD8-regulatory T cells and T cell clones presenting TCR peptide. Its implication for TCR vaccination against experimental autoimmune encephalomyelitis
Benichou et al.	1996	The influence of two distinct alloresponse pathways on the design of peptide-based strategies for allograft tolerance
Waaga et al.	1999	Major histocompatibility complex–derived peptides as novel forms of immunosuppression
Otto et al.	2002	Prolongation of small bowel allograft survival with a sequential therapy consisting of a synthetic MHC class II peptide and temporarily low-dose cyclosporine A